Aptorum Group Ltd Stock Price, News & Analysis

Aptorum Group (NASDAQ: APM) priced a registered direct offering of 1,000,000 Class A ordinary shares at $2.00 per share for expected gross proceeds of $2.0 million, with a concurrent private placement of unregistered warrants to buy up to 2,000,000 shares at $2.00 per share. Closing is expected on or about October 14, 2025, subject to customary conditions.

The warrants are exercisable upon issuance, expire 24 months after effectiveness of a resale registration statement, and could provide up to $4.0 million additional gross proceeds if fully exercised. Net proceeds are intended to fund expenses tied to the planned merger with DiamiR Biosciences and general working capital; the merger remains subject to contingencies including shareholder approval.

Aptorum Group (NASDAQ: APM) announced board and management changes tied to its planned all-stock merger with DiamiR Biosciences, expected to close in Q4 2025. Upon closing, DiamiR will become a wholly owned subsidiary and Aptorum will add Dr. Laura A. Philips as an independent director. DiamiR co-founder Dr. Kira Sheinerman will join the combined board as a director, and DiamiR CEO Dr. Alidad Mireskandari will join as President and Chief Operating Officer and take a board observer seat. The announcement highlights added expertise in molecular diagnostics, Alzheimer’s early-detection tests, and commercialization experience for the combined company.

Aptorum Group (NASDAQ: APM) and DiamiR Biosciences announced their joint presentation at the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 10, 2025, at 11 AM ET. The presentation will be delivered by DiamiR's CEO, Dr. Alidad Mireskandari, at the Lotte New York Palace Hotel in New York.

This presentation follows the companies' previously announced all-stock merger agreement from July 16, 2025, where DiamiR will become a wholly-owned subsidiary of Aptorum Group. The merger transaction is pending stockholder approval from both companies and is expected to close in Q4 2025.

DiamiR Biosciences and Aptorum Group (NASDAQ: APM) have announced that DiamiR has received Clinical Laboratory Evaluation Program (CLEP) Test Approval from the New York State Department of Health for its APOE Genotyping test.

This regulatory milestone enables DiamiR to provide validated APOE Genotyping molecular testing through its CLIA-certified and CAP-accredited clinical laboratory. The test can analyze various biological samples including blood, buccal swab, saliva, and tissue, and will be available to licensed healthcare providers in New York State and nationwide.

The approval expands access to a diagnostic tool for brain health assessment, particularly for neurodegenerative conditions like mild cognitive impairment and Alzheimer's disease.

Aptorum Group (NASDAQ: APM) has successfully regained compliance with Nasdaq's minimum bid price requirement, following its Class A ordinary shares maintaining a closing bid price of at least $1.00 for 10 consecutive business days from July 16 to July 30, 2025. This achievement comes before the October 14, 2025 deadline set by Nasdaq.

Additionally, the company announced on July 14, 2025, that it has entered into a definitive agreement for an all-stock merger with DiamiR Biosciences, a developer of blood-based tests for brain health and other diseases. Upon completion of the merger, DiamiR Biosciences, which operates a CLIA-licensed, CAP-accredited clinical laboratory in New Haven, CT, will become a wholly-owned subsidiary of Aptorum Group.

Aptorum Group (NASDAQ: APM) has announced a definitive agreement for an all-stock merger with DiamiR Biosciences, a developer of blood-based tests for brain health and other diseases. Upon merger completion, DiamiR will become a wholly-owned subsidiary of Aptorum while maintaining its name.

The combined entity will remain listed on the Nasdaq Stock Market, aiming to leverage DiamiR's CLIA-licensed, CAP-accredited clinical laboratory in New Haven, CT. The merger strategically combines Aptorum's biopharmaceutical capabilities with DiamiR's expertise in blood-based testing, particularly focusing on brain health, neurodegenerative diseases, oncology, and autoimmune indications.

Aptorum Group (NASDAQ: APM) has received a notification from Nasdaq Stock Market on April 15, 2025, regarding non-compliance with the minimum bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2).

The company has been granted a 180-calendar-day grace period until October 14, 2025, to regain compliance with the listing requirements. During this period, the trading of APM shares on Nasdaq will continue unaffected.

To address this situation, Aptorum Group is evaluating various options, including the possibility of implementing a reverse stock split. The biotechnology company has expressed its commitment to maintaining its Nasdaq listing and will pursue necessary measures to achieve compliance within the specified timeframe.

Aptorum Group (NASDAQ: APM) has announced a $3.0 million registered direct offering of 1,535,000 Class A Ordinary Shares at $2.00 per share. The clinical stage biopharmaceutical company, focused on oncology, autoimmune and infectious diseases, expects to close the offering around January 3, 2025, subject to customary closing conditions.

Maxim Group serves as the sole placement agent. The offering is made pursuant to an effective shelf registration statement on Form F-3. The company will file a prospectus supplement with the SEC, and the gross proceeds are estimated at $3.0 million before deducting placement agent fees and other offering expenses.

Aptorum Group (NASDAQ: APM) reported financial results for H1 2024, with a net loss of $2.7 million, improved from $6.6 million in H1 2023. The company announced the termination of its reverse takeover transaction with Yoov Group due to market conditions affecting funding availability.

Key financial highlights include: Research and development expenses decreased to $2.0 million from $3.2 million; General and administrative fees reduced to $0.3 million from $1.3 million; and Legal and professional fees declined to $0.4 million from $1.7 million. As of June 30, 2024, cash and restricted cash totaled $0.8 million with total equity of $13.2 million.